Positive Media Coverage Somewhat Unlikely to Affect Oasmia Pharmaceutical AB (OASM) Stock Price
News headlines about Oasmia Pharmaceutical AB (NASDAQ:OASM) have been trending positive this week, Accern reports. The research group identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Oasmia Pharmaceutical AB earned a news sentiment score of 0.38 on Accern’s scale. Accern also gave media stories about the company an impact score of 43.1300843342176 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Oasmia Pharmaceutical AB (OASM) traded up 9.70% during mid-day trading on Friday, reaching $1.13. The company had a trading volume of 30,400 shares. The firm has a 50-day moving average of $1.04 and a 200 day moving average of $1.79. Oasmia Pharmaceutical AB has a 1-year low of $0.85 and a 1-year high of $3.70. The company’s market capitalization is $47.50 million.
The business also recently disclosed a … dividend, which was paid on Monday, July 24th. Stockholders of record on Monday, July 17th were paid a $0.0185 dividend. The ex-dividend date was Thursday, July 13th.
COPYRIGHT VIOLATION NOTICE: “Positive Media Coverage Somewhat Unlikely to Affect Oasmia Pharmaceutical AB (OASM) Stock Price” was originally published by Daily Political and is owned by of Daily Political. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://www.dailypolitical.com/2017/08/13/positive-media-coverage-somewhat-unlikely-to-affect-oasmia-pharmaceutical-ab-oasm-stock-price.html.
About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB (publ) develops, produces, markets, and sells drugs for human and veterinary oncology primarily in Sweden. It focuses on manufacturing formulations based on cytostatics. The companys approved products include Paccal Vet-CA1 for the treatment of mammary carcinoma and squamous cell carcinoma in dogs; and Paclical for the treatment of ovarian cancer.
Receive News & Ratings for Oasmia Pharmaceutical AB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oasmia Pharmaceutical AB and related companies with MarketBeat.com's FREE daily email newsletter.